Product Code Database
Tavapadon (developmental code names CVL-751, PF-06649751) is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. It is under development by Cerevel Therapeutics, which acquired tavapadon from Pfizer in 2018. It is taken by mouth.
Tavapadon acts as a highly selective partial agonist of the dopamine D1 receptor (Ki = 9nM; = 65%) and the dopamine D5 receptor (Ki = 13nM; = 81%). It has no significant affinity or functional activity at the D2-like receptors (D2, D3, D4) (Ki ≥ 4,870 to 6,720nM). Tavapadon also shows biased agonist for Gs-coupled signaling at the D1-like receptors.
As of December 2024, tavapadon has completed phase 3 for Parkinson's disease.
|
|
